Study guide

7.2 Plain-Language Summaries and Patient Partnership

Certified Medical Publication Professional CMPP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Preparation Strategy

1.1 ISMPP CMPP Certification Overview, Eligibility & Exam Format 1.2 Recertification, Continuing Education (CE) Credits & ISMPP U 1.3 Core Reference Hierarchy, Primary Documents & Test-Taking Strategy

2 Chapter 2: Publication Planning: Strategy, Environment & Scientific Platform

2.1 Medical Publication Lifecycle & Strategic Planning Frameworks 2.2 Therapeutic Landscape Analysis, Unmet Needs & Gap Analysis 2.3 Scientific Communication Platforms and Evidence-Based Language

3 Chapter 3: Publication Planning: Governance, Steering Committees & Venue Selection

3.1 Publication Steering Committees: Charters, Roles & Scientific Governance 3.2 Target Audience Identification: HCPs, Patients, Payers & Regulators 3.3 Venue Selection, Open Access, and Congress Strategy

4 Chapter 4: Publication Planning: Operations, Contracting, Global Alignment & Compliance

4.1 Publication Agreements, Review Rights, Compensation & Disclosure 4.2 Milestones, Gantt Charts, Budgeting & Vendor/Agency Management 4.3 Global vs. Regional/Local Publication Alignment & Localization 4.4 Publication SOPs, Documentation, Quality Control & Audit Readiness

5 Chapter 5: Reporting Guidelines: Foundational Standards & Trial Reporting

5.1 EQUATOR and Design-Specific Reporting Guidelines 5.2 CONSORT 2025 & Flow Diagrams for Randomized Trials 5.3 SPIRIT 2025: Standard Protocol Items for Interventional Trials

6 Chapter 6: Reporting Guidelines: Observational, Reviews & Preclinical

6.1 PRISMA 2020 for Systematic Reviews & Meta-Analyses 6.2 STROBE & RECORD for Observational and Routinely Collected Data 6.3 ARRIVE 2.0 for In Vivo Animal Research

7 Chapter 7: Specialized Reporting, Plain Language Summaries & Congress Submissions

7.1 STARD 2015, CARE, and Specialized Reporting Guidelines 7.2 Plain-Language Summaries and Patient Partnership 7.3 GPCAP 2026: Congress Abstracts, Presentations & Encores 7.4 Digital Publication Features, Accessibility, and Social Dissemination

8 Chapter 8: Manuscript Lifecycle: Drafting, Peer Review, Open Access & Metrics

8.1 Manuscript Development, Author Review, and Sponsor Boundaries 8.2 Peer Review, Rebuttals, Revisions, and Appeals 8.3 Preprints, Creative Commons & Current Open-Access Requirements 8.4 Post-Publication Metrics and Correcting the Record

9 Chapter 9: Ethical Principles: GPP 2022, Authorship Criteria & Contributorship

9.1 Good Publication Practice 2022: Principles, Scope & Application 9.2 ICMJE Authorship Criteria and Qualification Scenarios 9.3 Nonauthor Contributors, Acknowledgments, and CRediT

10 Chapter 10: Ethics & Transparency: Ghostwriting, Writing Assistance, COI & Disclosure

10.1 Ghostwriting, Guest Authorship, and Authorship Disputes 10.2 Professional Medical Writing: Roles, Authorship, Disclosure & Funding 10.3 Disclosure of Interests and Publication Transparency 10.4 Open Payments, EFPIA Codes & Publication-Related Transfers of Value

11 Chapter 11: Compliance & Legal: Clinical Trial Registration, Data Sharing, Regulatory & Ethics

11.1 Trial Registration and Results Disclosure: US, EU, and ICMJE 11.2 Clinical-Trial Data-Sharing Statements and FAIR Principles 11.3 FDA SIUU Guidance & Promotional/Scientific Communication Boundaries 11.4 2024 Declaration of Helsinki, Ethics Review, Privacy & Copyright

7.2 Plain-Language Summaries and Patient Partnership

Key Takeaways Explain This Topic AI

A plain-language summary of a publication should communicate the same study accurately for its intended non-specialist audience, with balanced benefits, harms, limitations, and uncertainty.

GPP 2022 supports considering patient involvement and accessible publication formats, but it does not make patient partnership at study inception or a PLSP a universal requirement for every publication.

No single school-grade target applies to every PLSP; use audience research, venue guidance, plain-language principles, readability diagnostics, and user review rather than treating a score as proof of comprehension.

EU clinical-trial results summaries for laypersons are regulatory submissions distinct from optional journal PLSPs; the applicable regulation, CTIS guidance, trial status, and deadlines govern them.

Patients and advocates can be authors when they satisfy all four ICMJE criteria and may receive reasonable compensation for legitimate advisory work, never for authorship status or favorable conclusions.

Last updated: October 2026

Plain-Language Summaries and Patient Partnership

A plain-language summary of a publication (PLSP) explains a peer-reviewed work for people who may not share the authors' technical training. Its purpose is access to the same science, not simplification into advertising. The intended audience may include patients, caregivers, advocates, non-specialist clinicians, policymakers, or the public, and their information needs may differ.

Preserve the scientific meaning

A defensible PLSP reports the research question, participants, methods, main findings, important harms, limitations, and what the study can and cannot establish. Numerical results should keep useful denominators, absolute effects, time frames, and uncertainty. “The risk fell by 50%” is incomplete if the actual change was from 2 in 1,000 to 1 in 1,000. “No significant difference” should not be rewritten as “the treatments were the same.”

Avoid promotional superlatives such as “revolutionary,” “breakthrough,” “miracle,” or “completely safe.” A summary linked to an industry-funded study should identify funding, writing support, and conflicts as required by the venue. It should not add claims, audiences, subgroup conclusions, or comparisons absent from the parent work.

Useful drafting practices include:

  • define technical terms at first use and use a consistent term thereafter;
  • favor short, direct sentences and active constructions where accuracy permits;
  • use headings, white space, lists, and visual explanations to reduce cognitive load;
  • explain randomization, comparator, endpoints, and uncertainty in concrete language;
  • use natural frequencies and absolute effects when useful;
  • report important adverse events and discontinuations, not benefits alone;
  • distinguish association from causation and exploratory from prespecified results;

provide accessible formats and meaningful alternative text for visuals.

Readability is a diagnostic, not a mandate

Flesch Reading Ease, Flesch–Kincaid Grade Level, SMOG, and similar tools count features such as sentence length and syllables. They can reveal dense prose, but they do not measure factual accuracy, health literacy, cultural fit, visual accessibility, or whether a reader understood the message. Medical terms can inflate a grade score even when well explained.

There is no universal GPP rule that every PLSP must fall between US grades 6 and 8. The appropriate target depends on the audience, venue, language, condition, legal requirements, and local guidance. Use a stated target when a journal, funder, regulator, or organization supplies one. Otherwise, document the intended audience, use readability tools as diagnostics, and seek review from representative readers where feasible.

Translation also requires more than word substitution. Use qualified translation and cultural adaptation processes appropriate to the risk, and verify numbers, terminology, labels, and layout after translation. Back translation can be useful in some workflows but is not a universal guarantee of quality.

Patient involvement

Patients and caregivers can improve topic prioritization, outcome relevance, terminology, visual design, interpretation, dissemination channels, and accessibility. Meaningful involvement starts with a defined purpose and an opportunity to influence decisions. It should not be tokenistic or used to manufacture endorsement.

GPP 2022 encourages consideration of patients as publication partners and audiences. It does not state that every publication must include a patient at study inception or that every article must have a PLSP. Plan involvement at a stage when it can matter, disclose roles, provide training or support, address accessibility, and explain how feedback was handled. Protect participants from pressure to reveal health details or publicly endorse a product.

Authorship, acknowledgment, and compensation

Patient status neither qualifies nor disqualifies a contributor from authorship. Apply the same four ICMJE criteria: substantial contribution; drafting or critical intellectual revision; final approval; and accountability. Someone who advises on terminology but does not meet all criteria may be acknowledged, with permission, and their contribution can be described.

Reasonable compensation for legitimate advisory time, preparation, accessibility needs, travel, childcare, or other agreed expenses may reduce barriers to participation. Use a written agreement and a defensible rate or policy. Compensation must not purchase authorship, favorable interpretation, silence about harms, or journal acceptance. Disclose relevant relationships under applicable policies.

Regulatory lay summaries are different

A journal PLSP should not be confused with a clinical-trial results summary for laypersons required under the EU Clinical Trials Regulation for trials within its scope. The regulatory summary is submitted through the Clinical Trials Information System and is governed by the regulation and current implementing guidance, including applicable timing and content rules. A journal PLSP is an editorial publication feature unless a journal, funder, or other policy makes it required.

One document does not automatically replace the other. They may have different data cutoffs, templates, audiences, review processes, identifiers, and timing. The team should map each obligation to the correct source and keep the scientific story consistent.

A review checklist

Before release, ask:

Who is the intended reader, and was that audience involved in review where feasible?

Do all numbers, denominators, time points, comparators, and conclusions match the source?

Are benefits, harms, limitations, and uncertainty balanced?

Does the summary avoid promotional language and unsupported causal claims?

Are authorship, contributor roles, funding, and writing support handled transparently?

Does the format meet venue and accessibility requirements?

Are translation, privacy, consent, and local regulatory needs addressed?

Is this a journal PLSP, a regulatory lay summary, or both as separate deliverables?

Tip

When an exam option treats a grade-level score as the only quality test, reject it. Prefer an accurate, audience-tested, accessible summary whose language and layout follow the controlling venue or regulatory requirement.